FDA 483 - Georgia Eye Bank, Inc. - May 24, 2019

An FDA inspection of Georgia Eye Bank, Inc. in Atlanta, GA, identified a significant issue regarding process validation. The firm failed to establish and implement procedures to validate critical corneal processing methods, specifically for DMEK, DSEK, and LIKE procedures. This indicates a lack of control over processes that cannot be fully verified by inspection and tests.